Navigation Links
Find New Cancer Treatments at cureLauncher
Date:1/24/2013

Bloomfield Hills, MI (PRWEB) January 24, 2013

Less than 5 percent of Americans know where to find information about clinical trials, according to the Center for Information & Study on Clinical Research. cureLauncher solves that problem. It gives everyone a place to find new treatments and connect with lifesaving treatment options.

Now, cureLauncher has every enrolling breast cancer trial in the country available on its website. There are 400 trials at 7,500 locations across the U.S. that offer new breast cancer treatment options. cureLauncher has translated the complex, medical terminology into easy to understand English.

When people visit cureLauncher, they can review information about these trials and the entry questions to see if a trial is right for them. Anyone can complete the Request Form to participate or call cureLauncher directly to see if they qualify. This service is free to all users.

cureLauncher’s founders, Stephen Goldner and David Fuehrer, appeared on the Stupid Cancer Radio Program live from New York City on January 21st to discuss trial options. “cureLauncher makes it easy for people to find treatment that’s right for them”, said David Fuehrer. “Our mission is to provide a place where people feel comfortable learning about clinical trials and cutting edge, new medical treatments”.

Dr. Max Wicha, Director of the University of Michigan’s Cancer Center, was on the Stupid Cancer Show with cureLauncher. “Only about 3 percent of cancer patients decide to enter a clinical trial, even though the v
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. Cornell bioengineers discover the natural switch that controls spread of breast cancer cells
2. New Shared Synthetic Replikin Cancer Vaccines
3. NextBio Teams With Emory University and the Aflac Cancer Center to Improve Outcomes for Children with Medulloblastoma
4. Genetic basis of high-risk childhood cancer points to possible new drug treatment strategy
5. Antigen Express AE37 Breast Cancer Vaccine Featured In "Micro-Cap Review" Interview
6. University of Colorado Cancer Center Study Finds That Body's Ibuprofen, SPARC, Reduces Inflammation and Thus Bladder Cancer Development and Metastasis
7. The Blood Sugar-Cardiac-Cancer Connection
8. Join Cato BioVentures and Cancer Advances at Biotech Showcase 2013 & J.P. Morgan 31st Annual Healthcare Conference
9. Game changing diagnostic & prognostic prostate cancer genetic tests revealed by Jefferson
10. UroToday Launches New Prostate Cancer Focused Content Including Immunotherapy for Metastatic Castration-resistant Patients
11. Breast cancer cells growing in 3D-matrix revert to normal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Canada (PRWEB) January 15, 2014 This ... on nonclinical and clinical safety assessment in biosimilars. , ... path for biosimilar drug development, however the complex nature ... to quality, safety and efficacy extremely challenging. Based on ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 The Microcompetition with ... major disease. One of these latent viruses is the Epstein ... arthritis (RA). Rheumatoid arthritis (RA) is a chronic inflammatory disease ... a study found that RA patients have high concentrations of ...
(Date:1/15/2014)... AudioNotch is the internet's leading provider of Notched ... tinnitus. Patients listen to sound therapy that is tailor-made ... weeks to months, their tinnitus volume decreases. , AudioNotch has ... and Notched White Noise. Now, AudioNotch is pleased to announce ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company developing ... simulated embryonic conditions, today announced that they have entered ... for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent cell ... an amendment to the existing license between Histogen and ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... ArborGen, LLC, a leader in forest tree ... field trials that are utilizing technology in-licensed from Senesco ... The two companies had previously announced that trees that ... in 3-year-old field trials. , , Selected ...
... published in July 7, 2009 Issue of Proceedings of the ... QUEBEC CITY, July 7 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: ... focused on endocrine therapy and oncology, today announced publication in ... of Sciences (PNAS), of new data supporting the use of ...
... Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ... treatments for human disease, announced today that it has initiated ... , the company,s oral drug candidate for managing gastrointestinal symptoms ... is designed to reduce serotonin production in patients with metastatic ...
Cached Biology Technology:ArborGen and Senesco Announce Wood Quality Results 2ArborGen and Senesco Announce Wood Quality Results 3ArborGen and Senesco Announce Wood Quality Results 4AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction 2AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction 3AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction 4Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome 2Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome 3Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome 4
(Date:4/23/2014)... new study from the Indiana University School of Public ... and heart disease by finding a strong association between ... coronary heart disease. , The study found that heme ... by 57 percent, while no association was found between ... sources, and coronary heart disease. , The study was ...
(Date:4/23/2014)... and Spanish . ... released its Conservation Assessment for the Big Bend-Ro Bravo ... 29 priority conservation areas in a region straddling the ... in the states of Texas, Coahuila, and Chihuahua. This ... inhabited by rare and endangered plants and animals, and ...
(Date:4/23/2014)... evidence that the source of a unique rhythmic sound, ... the "bio-duck," is the Antarctic minke whale ( Balaenoptera ... in the 1960s who thought it sounded like a ... locations in the Southern Ocean, but its source has ... an international team of researchers deployed acoustic tags on ...
Breaking Biology News(10 mins):Study: Iron consumption can increase risk for heart disease 2Conservation priorities released for several protected areas along US-Mexico border 2Conservation priorities released for several protected areas along US-Mexico border 3Scientists identify source of mysterious sound in the Southern Ocean 2Scientists identify source of mysterious sound in the Southern Ocean 3
... YORK, NY and PALO ALTO, CA January 22, 2009 ... four young scientists with novel approaches to fighting cancer have ... of $450,000 over three years is awarded each year to ... have a major impact on the prevention, diagnosis and treatment ...
... 22, 2009--Biotechnology companies are building on what they ... decade and are expected to drive this market ... Genetic Engineering and Biotechnology News ( GEN ... number of advantages, including reducing reagent consumption, increasing ...
... three-year study to conserve and restore endangered horse mussel ... the University,s marine research and outreach centre in Portaferry ... of Biological Sciences, will provide scientific and technological research ... to restore it. Horse mussel reefs are important ...
Cached Biology News:2009 Damon Runyon-Rachleff Innovation Awards granted for pioneering ideas in cancer research 22009 Damon Runyon-Rachleff Innovation Awards granted for pioneering ideas in cancer research 32009 Damon Runyon-Rachleff Innovation Awards granted for pioneering ideas in cancer research 4GEN reports on growing reliance on microfluidics technology 2Queen's University Belfast works to save Strangford horse mussels 2
B2-Microgloulin...
... utilizies CTI Molecular Imaging's proprietary Focus™ detector ... volume as the R4. The microPET ... any commerically avaiable PET scanner. Focus ... of any scinitallor based PETsystems. The ...
...
... product has been developed to significantly increase ... proteins. Stability is increased at room ... centigrade. This product is subjected to ... or azide. This formulation insures consistently ...
Biology Products: